PMCCPMCCPMCC

Search tips
Search criteria 

Advanced

 
Logo of frontmedicineLink to Publisher's site
 
Front Med (Lausanne). 2017; 4: 18.
Published online 2017 March 8. doi:  10.3389/fmed.2017.00018
PMCID: PMC5340762

MAGE-A Antigens and Cancer Immunotherapy

Abstract

MAGE-A antigens are expressed in a variety of cancers of diverse histological origin and germinal cells. Due to their relatively high tumor specificity, they represent attractive targets for active specific and adoptive cancer immunotherapies. Here, we (i) review past and ongoing clinical studies targeting these antigens, (ii) analyze advantages and disadvantages of different therapeutic approaches, and (iii) discuss possible improvements in MAGE-A-specific immunotherapies.

Keywords: MAGE-A, cancer–testis antigens, cancer immunotherapy, clinical trials, adoptive immunotherapy

MAGE-A Tumor-Associated Antigens

MAGE-A were the first human tumor-associated antigens identified at the molecular level (1). They belong to the larger family of cancer/testis antigens (CTA), whose expression is consistently detected in cancers of different histological origin and germinal cells (2). The MAGE-A sub-family includes 12 highly homologous genes located on chromosome Xq28 (3, 4). Specific gene products have been identified by immunohistochemistry in cancers of different histological origin, including high percentages of non-small cell lung cancers (NSCLC), bladder cancers, esophageal and head and neck cancers, and sarcomas (5). These antigens are also frequently expressed in triple negative breast cancers (6), myeloma (7), and Reed–Sternberg cells (8) in Hodgkin’s disease, with the highest frequency being detected in synovial sarcoma (9). Among healthy tissues, the expression of specific members of the family has been observed in spermatogonia, placenta (10), and fetal ovary (11). However, recently, MAGE-A1 and -A12 genes have been shown to be expressed in CNS as well, as discussed below (12).

Functional Aspects of MAGE-A Antigens

Preferential intracellular location may be different for different antigens, e.g., mostly cytoplasmic for MAGE-A1, -A3, and -A4, but mostly nuclear for MAGE-A10 (1316).

Functions are still unclear, although different studies have associated MAGE-A2, -A3/6, and -A9 expression with pro-tumorigenic activities such as p53 dysregulation (1719), enhanced tumor cell proliferation potential, or maintenance of a cancer-stem cell-like functional profile (20).

In a variety of tumors of different histological origin, a clear correlation between expression of MAGE-A antigens and poor prognosis has been observed. In this context, data on bladder cancer (21, 22), NSCLC (23, 24), head and neck cancers (2527), and ovarian cancer (28, 29) have consistently been reported. Indeed, MAGE-A antigen expression, at the gene and protein level, has repeatedly been shown to be associated with widespread DNA demethylation frequently observed in advanced cancers. On the same line, it has been shown to be inducible by demethylating agents, including chemotherapeutic compounds widely used in cancer treatment such as 5-aza-2′-deoxycytidine (30, 31), thus realistically envisaging the possibility of treatments combining chemotherapy and specific vaccination (32).

Immunogenicity of MAGE-A Antigens

Although peptides restricted by both HLA classes I and II have been identified (33), naturally occurring adaptive immune responses to MAGE-A antigens are usually characterized by a very low frequency of specific precursors (34) in both healthy donors and patients bearing cancers expressing them (35). However, responses to MAGE-A10 have been more frequently detected (36, 37). Responses in tumor-associated lymphocytes (TIL) have seldom been explored, but we have observed that MAGE-A10-specific CTL could be expanded from TIL infiltrating NSCLC displaying a high expression of the target antigen (38). On the other hand, CTL recognizing peptide motifs shared by multiple MAGE-A proteins may be generated from peripheral blood from patients and healthy donors (39). Most recently, tumor reactive CD8+ T cells, isolated based on their expression of activation marker (PD-1) from peripheral blood of melanoma patients, have been shown to relatively frequently target MAGE-A antigens (40).

Clinical Trials Targeting MAGE-A Antigens

In the past 10 years (2006–2016), a total of 44 clinical trials could be identified in “https://clinicaltrials.gov” database using “MAGE-A” as keyword: a total of 16 phase 0 or I, 13 phase I/II, 13 phase II, and 2 phase III studies. Regarding immunogen formulations, 16 studies utilized entire proteins in the presence or absence of adjuvants (41, 42), 11 used peptides (4345), 6 used mRNA-transfected DC (46, 47), 1 was based on tumor cell lysate-pulsed DC, 2 took advantage of recombinant viral vectors (48, 49), and more recently, 6 and 2 trials, respectively, have focused on adoptive treatments by using specific T cell receptor (TCR)-transduced T cells (12) or expanded CTL (50).

Efficacy clinical data published so far, from patients immunized in the context of the 15 larger studies (phase II or III, Table S1 in Supplementary Material) mainly using MAGE-A protein (n = 11), do not appear to support significant clinical effectiveness (51).

Of interest, a chronological analysis of these 44 studies clearly underlines a strategy shift in the most recent years. Indeed, in the past 4 years, among the (only) 10 clinical studies initiated and including MAGE-A as antigens, there are no phase II or III studies. Moreover, the majority of the phase I or I/II studies are based on adoptive cell transfer. This “shift” in MAGE-A translational research strategy clearly results from the combined effect of “protein/peptide” efficacy failure and from the confidence generated by new approaches focusing on personalized effector T-cell treatment. In addition, one should also mention the shift in target paradigm from classical TAA to neo-antigens also contributing to the decreased use of MAGE-A antigens.

MAGE-A3 Protein as Immunogen

One of the most important clinical trials ever performed in MAGE-A cancer immunotherapy, involving thousands of patients with NSCLC, was focusing on the administration of recombinant MAGE-A3 protein together with adjuvants (52, 53). Despite promising initial data and the proven ability of the immunization protocol to induce detectable humoral responses in vaccinated patients (54), disease-free interval in patients with completely resected stage IB, II, and IIIA NSCLC did not appear to be significantly prolonged, as compared to patients of control group, in phase III studies in the context of an adjuvant therapy setting (41).

Why did these trials fail to reach efficacy? First, similar to MAGE-A antigens, a large majority of classical TAA-specific cancer vaccines clinically tested so far have been shown to induce heterogeneous immune responses rarely resulting in significant clinical effects.

However, specific issues should be considered for CTA-specific immunization. For instance, MAGE-A CTA expression, a pre-requisite for the eligibility of patients for treatment in these studies, has usually been assessed at the gene level by quantitative RT-PCR (RT-qPCR) (41, 54), which cannot provide insights into the actual numbers of CTA-positive tumor cells. Immunohistochemical studies using available MAGE-A-specific mAbs consistently underline that expression of these antigens might be highly heterogeneous in cancerous tissues with high expression often only detectable in relatively low percentages of tumor cells (10, 55). Remarkably, due to the high homology of sequences from different components of the MAGE-A family, a majority of currently available reagents do recognize multiple antigens. Our own experience based on the use of a MAGE-A10 highly specific mAb (Figure (Figure1)1) suggests that expression of these antigens may be highly heterogeneous in a variety of tumors of different histological origin, with percentages of “positive” cells ranging between 5 and >60% (16). One could speculate that criteria based on the expression of target antigen(s), at the protein level, in high percentages of tumor cells and in multiple areas of primary and metastatic cancers could be applied for a more stringent selection of patients potentially eligible for MAGE-A-targeted antitumor immunization. Additionally, it might be of interest to verify the expression of the target MAGE-A antigen in recurrent tumors following specific immunization protocols, to verify possible selective immune editing (56). It is worth noting, however, that successful antigen-specific vaccination has also been shown to be able to promote responsiveness against unrelated antigens, the so-called “antigen spreading” phenomenon (57), thus potentially overcoming the requirement for a uniform expression of target antigens in tumors to be treated.

Figure 1
Heterogeneity of MAGE-A10 expression at the protein level. Melanoma tissues from a multi-tumor tissue microarray were stained with a MAGE-A10-specific reagent by standard techniques, as previously detailed (16). Antigen expression displays a high heterogeneity, ...

Importantly, the recombinant protein used in most efficacy studies was shown to induce humoral response and HLA class II-restricted lymphoproliferation, as expectable (41, 53, 54). However, the ability of these antigen formulations to promote class I-restricted responses appears to be more limited. One could speculate that libraries of overlapping “long” peptides (58), or highly immunogenic recombinant vectors (38, 59), could be more effective in this regard.

Heterogeneous Expression of MAGE-A Genes in Primary and Metastatic Cancers

Studies from our group clearly document the heterogeneity of MAGE-A antigens expression at the gene expression level as well. We tested by RT-qPCR the expression of Mage-A1, -A2, -A3, -A4, -A10, and -A12 genes in primary NSCLC from 33 patients (Table (Table1).1). In keeping with published data (23, 24), a total of 22 tumors (66%) showed evidence of expression of at least one of the antigens under investigation. Similar to recently published data in oral cancer (60), out of these patients with MAGE-A+ NSCLC, 10 (45%) had lymph nodes (LN) showing evidence of tumor metastasis, as compared with only 2 (18%) from the 11 MAGE-A(−) primary tumors. Interestingly, among the 10 metastatic LN from MAGE-A+ primary cancers, only half showed evidence of MAGE-A gene expression. Furthermore, in four LN, classified as non-metastatic, based on pathological evidence, expression of MAGE-A genes could be observed by RT-qPCR. Intriguingly, among LN associated with MAGE-A− primary cancers, 1/2 and 1/8 metastatic and non-metastatic samples, respectively, showed evidence of MAGE-A gene expression.

Table 1
MAGE-A gene expression, as detected by RT-qPCR in primary non-small cell lung cancers (NSCLC) and in corresponding lymph nodes (LN) showing evidence of metastatic outgrowth by standard clinical pathology techniques.

Taken together, these data suggest a higher sensitivity of RT-qPCR as compared to standard techniques for the detection of cancer cells within LN draining primary tumor tissues. Most importantly, however, they confirm the dynamic nature of MAGE-A antigens expression during cancer progression and may support the concept of combination therapies including treatments promoting MAGE-A antigen expression together with specific immunization procedures (61).

Adoptive Immunotherapies

In recent clinical studies, effector T cells, transduced with vectors encoding for specific TCRs recognizing peptides from MAGE-A3 or MAGE-4, have been adoptively transferred into patients bearing tumors expressing these antigens. Unfortunately, upon anti-MAGE-A3, HLA-A0201-restricted TCR gene therapy, despite measurable clinical responses in some patients, treatment-related severe adverse events and deaths were also reported. These events may possibly be due to the high affinity of these TCRs (see below) and to the recognition (“on-target/off-tumor”) of highly homologous peptide(s) from other MAGE-A proteins expressed in the CNS (12, 62). Similarly, myocardial toxicity, resulting in treatment related death, has also been observed following gene therapy with a MAGE-A3-specific HLA-A0101-restricted TCR (63, 64). In the latter case, the “off-target” effect was attributed to the high homology between the target peptide and a peptide from Titin muscle protein.

It is worth noting that the TCR transduced into T cells in the first study originally derived from “humanized” mice expressing HLA-A0201 and its affinity toward the target antigen was further improved by site-directed mutagenesis (65), thus increasing the chances of “on-target_off-tumor” adverse events affecting tissues characterized by low but detectable expression of defined MAGE-A antigens (12). The affinity of the TCR used in the second study, originally derived from a patient immunized with a recombinant viral vector (66), was also enhanced by site-directed mutagenesis.

By contrast, T cells expressing a MAGE-A4-specific TCR have been safely used in adoptive immunotherapy of patients with recurrent esophageal cancer (67).

Taken together, these data suggest that the clinical use of enhanced TCR effectors targeting MAGE-A antigens for cancer immunotherapy should be carefully evaluated in order to minimize potential “off-tumor” side effects.

However, natural MAGE-A-specific TCRs, from clones derived from tumor bearing patients or healthy donors, might also be of interest. Such CTLs would probably be characterized by a lower affinity for cognate HLA–class I peptide complex and possibly by a lower antitumor effector potential, but they would also likely have less toxic side effects. Considering the cumulative potency related to the high numbers of transduced cells usually infused into treated patients, and their ability to proliferate and generate “memory,” the effectiveness of this type of treatment should reasonably be further tested.

Conclusions

Taken together, published data may suggest that therapeutic strategies targeting MAGE-A antigens have so far failed to fulfill the promise of representing effective tools for cancer treatment. However, the understanding of mechanisms controlling immune response as a whole and cancer-specific immune responses in the tumor microenvironment in particular has made enormous progress in the past decade, generating an unprecedented “momentum” for cancer immunotherapy.

Successful utilization of therapeutic mAbs recognizing “immunological checkpoints” is currently generating enormous interest in clinical oncology. Their mechanisms of actions (MoA) are not fully clarified (68, 69). However, one of the main MoA is arguably represented by the “release of brakes” hampering T cell responses specific for tumor-specific or associated antigens. This hypothesis is supported, for instance, by the higher effectiveness of treatment with anti CTLA-4 therapeutic mAbs in cancers characterized by a high mutational load, likely to result in a higher expression of mutated proteins potentially recognized as “non-self” by the adaptive immune system (70). It is therefore reasonable to postulate that adequately timed combinations of vaccination procedures and administrations of therapeutic “checkpoint inhibitor” specific mAbs could be of high clinical relevance. Within this framework, a critical point might be represented by the choice of antigens of potential clinical use. Neo-antigens, e.g., tumor-specific mutated proteins have been successfully identified by whole exome sequencing (7173), and the expression of defined antigenic “non-self” peptides associated with restricting HLA class I determinants may be detected by mass spectrometry techniques (74). Although highly appealing, the “personal” nature of neo-antigens might possibly also represent their Achilles’ heel, not only because of regulatory hurdles (75) but also because it would likely prevent the performance of conventional randomized trials, thereby complicating a reliable assessment of the effectiveness of innovative treatment procedures.

Based on these considerations, vaccination with tumor-associated or CTA could still realistically find an important place in cancer immunotherapy in the era of “immunological checkpoint” inhibitors (76). Considering that MAGE-A antigens are expressed in tumors with poor prognosis and a scarcity of therapeutic options, such as TNB, and lung and esophageal cancers, it is easy to predict that the interest of the scientific community in CTA might actually be revived in the light of the enormous advances in cancer immunotherapy of the last years.

Author Contributions

All authors participated in writing the manuscript and/or revising it critically for important intellectual content or providing the data mentioned in the manuscript.

Conflict of Interest Statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Funding

Part of this work was funded by the Swiss National Science Foundation; grant number: 310030_149745.

Supplementary Material

The Supplementary Material for this article can be found online at http://journal.frontiersin.org/article/10.3389/fmed.2017.00018/full#supplementary-material.

References

1. van der Bruggen P, Traversari C, Chomez P, Lurquin C, De Plaen E, Van den Eynde B, et al. A gene encoding an antigen recognized by cytolytic T lymphocytes on a human melanoma. Science (1991) 254:1643–7.10.1126/science.1840703 [PubMed] [Cross Ref]
2. Simpson AJ, Caballero OL, Jungbluth A, Chen YT, Old LJ.. Cancer/testis antigens, gametogenesis and cancer. Nat Rev Cancer (2005) 5:615–25.10.1038/nrc1669 [PubMed] [Cross Ref]
3. Chomez P, De Backer O, Bertrand M, De Plaen E, Boon T, Lucas S.. An overview of the MAGE gene family with the identification of all human members of the family. Cancer Res (2001) 61:5544–51. [PubMed]
4. De PE, Arden K, Traversari C, Gaforio JJ, Szikora JP, De SC, et al. Structure, chromosomal localization, and expression of 12 genes of the MAGE family. Immunogenetics (1994) 40:360–9.10.1007/BF01246677 [PubMed] [Cross Ref]
5. Juretic A, Spagnoli GC, Schultz-Thater E, Sarcevic B.. Cancer/testis tumour-associated antigens: immunohistochemical detection with monoclonal antibodies. Lancet Oncol (2003) 4:104–9.10.1016/S1470-2045(03)00982-3 [PubMed] [Cross Ref]
6. Curigliano G, Viale G, Ghioni M, Jungbluth AA, Bagnardi V, Spagnoli GC, et al. Cancer-testis antigen expression in triple-negative breast cancer. Ann Oncol (2011) 22:98–103.10.1093/annonc/mdq325 [PubMed] [Cross Ref]
7. Van BN, Brasseur F, Godelaine D, Hames G, Ferrant A, Lehmann F, et al. Genes encoding tumor-specific antigens are expressed in human myeloma cells. Blood (1999) 94:1156–64. [PubMed]
8. Chambost H, Van Baren N, Brasseur F, Godelaine D, Xerri L, Landi SJ, et al. Expression of gene MAGE-A4 in Reed-Sternberg cells. Blood (2000) 95:3530–3. [PubMed]
9. Antonescu CR, Busam KJ, Iversen K, Kolb D, Coplan K, Spagnoli GC, et al. MAGE antigen expression in monophasic and biphasic synovial sarcoma. Hum Pathol (2002) 33:225–9.10.1053/hupa.2002.31295 [PubMed] [Cross Ref]
10. Jungbluth AA, Silva WA, Jr, Iversen K, Frosina D, Zaidi B, Coplan K, et al. Expression of cancer-testis (CT) antigens in placenta. Cancer Immun (2007) 7:15. [PMC free article] [PubMed]
11. Nelson PT, Zhang PJ, Spagnoli GC, Tomaszewski JE, Pasha TL, Frosina D, et al. Cancer/testis (CT) antigens are expressed in fetal ovary. Cancer Immun (2007) 7:1. [PMC free article] [PubMed]
12. Morgan RA, Chinnasamy N, Abate-Daga D, Gros A, Robbins PF, Zheng Z, et al. Cancer regression and neurological toxicity following anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 36:133–51.10.1097/CJI.0b013e3182829903 [PMC free article] [PubMed] [Cross Ref]
13. Kocher T, Schultz-Thater E, Gudat F, Schaefer C, Casorati G, Juretic A, et al. Identification and intracellular location of MAGE-3 gene product. Cancer Res (1995) 55:2236–9. [PubMed]
14. Landry C, Brasseur F, Spagnoli GC, Marbaix E, Boon T, Coulie P, et al. Monoclonal antibody 57B stains tumor tissues that express gene MAGE-A4. Int J Cancer (2000) 86:835–41.10.1002/(SICI)1097-0215(20000615)86:6<835::AID-IJC12>3.0.CO;2-N [PubMed] [Cross Ref]
15. Schultz-Thater E, Juretic A, Dellabona P, Luscher U, Siegrist W, Harder F, et al. MAGE-1 gene product is a cytoplasmic protein. Int J Cancer (1994) 59:435–9.10.1002/ijc.2910590324 [PubMed] [Cross Ref]
16. Schultz-Thater E, Piscuoglio S, Iezzi G, Le MC, Zajac P, Carafa V, et al. MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies. Int J Cancer (2011) 129:1137–48.10.1002/ijc.25777 [PubMed] [Cross Ref]
17. Marcar L, Maclaine NJ, Hupp TR, Meek DW.. Mage-A cancer/testis antigens inhibit p53 function by blocking its interaction with chromatin. Cancer Res (2010) 70:10362–70.10.1158/0008-5472.CAN-10-1341 [PubMed] [Cross Ref]
18. Monte M, Simonatto M, Peche LY, Bublik DR, Gobessi S, Pierotti MA, et al. MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agents. Proc Natl Acad Sci U S A (2006) 103:11160–5.10.1073/pnas.0510834103 [PubMed] [Cross Ref]
19. Yang B, O’Herrin SM, Wu J, Reagan-Shaw S, Ma Y, Bhat KM, et al. MAGE-A, mMage-b, and MAGE-C proteins form complexes with KAP1 and suppress p53-dependent apoptosis in MAGE-positive cell lines. Cancer Res (2007) 67:9954–62.10.1158/0008-5472.CAN-07-1478 [PubMed] [Cross Ref]
20. Costa FF, Le Blanc K, Brodin B.. Concise review: cancer/testis antigens, stem cells, and cancer. Stem Cells (2007) 25:707–11.10.1634/stemcells.2006-0469 [PubMed] [Cross Ref]
21. Bergeron A, Picard V, LaRue H, Harel F, Hovington H, Lacombe L, et al. High frequency of MAGE-A4 and MAGE-A9 expression in high-risk bladder cancer. Int J Cancer (2009) 125:1365–71.10.1002/ijc.24503 [PubMed] [Cross Ref]
22. Kocher T, Zheng M, Bolli M, Simon R, Forster T, Schultz-Thater E, et al. Prognostic relevance of MAGE-A4 tumor antigen expression in transitional cell carcinoma of the urinary bladder: a tissue microarray study. Int J Cancer (2002) 100:702–5.10.1002/ijc.10540 [PubMed] [Cross Ref]
23. Bolli M, Kocher T, Adamina M, Guller U, Dalquen P, Haas P, et al. Tissue microarray evaluation of melanoma antigen E (MAGE) tumor-associated antigen expression: potential indications for specific immunotherapy and prognostic relevance in squamous cell lung carcinoma. Ann Surg (2002) 236:785–93.10.1097/01.SLA.0000036266.09823.6C [PubMed] [Cross Ref]
24. Gure AO, Chua R, Williamson B, Gonen M, Ferrera CA, Gnjatic S, et al. Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer. Clin Cancer Res (2005) 11:8055–62.10.1158/1078-0432.CCR-05-1203 [PubMed] [Cross Ref]
25. Cuffel C, Rivals JP, Zaugg Y, Salvi S, Seelentag W, Speiser DE, et al. Pattern and clinical significance of cancer-testis gene expression in head and neck squamous cell carcinoma. Int J Cancer (2011) 128:2625–34.10.1002/ijc.25607 [PubMed] [Cross Ref]
26. Figueiredo DL, Mamede RC, Spagnoli GC, Silva WA, Jr, Zago M, Neder L, et al. High expression of cancer testis antigens MAGE-A, MAGE-C1/CT7, MAGE-C2/CT10, NY-ESO-1, and gage in advanced squamous cell carcinoma of the larynx. Head Neck (2011) 33:702–7.10.1002/hed.21522 [PubMed] [Cross Ref]
27. Laban S, Atanackovic D, Luetkens T, Knecht R, Busch CJ, Freytag M, et al. Simultaneous cytoplasmic and nuclear protein expression of melanoma antigen-A family and NY-ESO-1 cancer-testis antigens represents an independent marker for poor survival in head and neck cancer. Int J Cancer (2014) 135:1142–52.10.1002/ijc.28752 [PubMed] [Cross Ref]
28. Daudi S, Eng KH, Mhawech-Fauceglia P, Morrison C, Miliotto A, Beck A, et al. Expression and immune responses to MAGE antigens predict survival in epithelial ovarian cancer. PLoS One (2014) 9:e104099.10.1371/journal.pone.0104099 [PMC free article] [PubMed] [Cross Ref]
29. Xu Y, Wang C, Zhang Y, Jia L, Huang J.. Overexpression of MAGE-A9 is predictive of poor prognosis in epithelial ovarian cancer. Sci Rep (2015) 5:12104.10.1038/srep12104 [PMC free article] [PubMed] [Cross Ref]
30. De SC, De BO, Faraoni I, Lurquin C, Brasseur F, Boon T.. The activation of human gene MAGE-1 in tumor cells is correlated with genome-wide demethylation. Proc Natl Acad Sci U S A (1996) 93:7149–53.10.1073/pnas.93.14.7149 [PubMed] [Cross Ref]
31. Weber J, Salgaller M, Samid D, Johnson B, Herlyn M, Lassam N, et al. Expression of the MAGE-1 tumor antigen is up-regulated by the demethylating agent 5-aza-2’-deoxycytidine. Cancer Res (1994) 54:1766–71. [PubMed]
32. Karpf AR.. A potential role for epigenetic modulatory drugs in the enhancement of cancer/germ-line antigen vaccine efficacy. Epigenetics (2006) 1:116–20.10.4161/epi.1.3.2988 [PMC free article] [PubMed] [Cross Ref]
33. Novellino L, Castelli C, Parmiani G.. A listing of human tumor antigens recognized by T cells: March 2004 update. Cancer Immunol Immunother (2005) 54:187–207.10.1007/s00262-004-0560-6 [PubMed] [Cross Ref]
34. Chaux P, Vantomme V, Coulie P, Boon T, van der Bruggen P.. Estimation of the frequencies of anti-MAGE-3 cytolytic T-lymphocyte precursors in blood from individuals without cancer. Int J Cancer (1998) 77:538–42.10.1002/(SICI)1097-0215(19980812)77:4<538::AID-IJC11>3.0.CO;2-2 [PubMed] [Cross Ref]
35. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al. Tumor regression responses in melanoma patients treated with a peptide encoded by gene MAGE-3. Int J Cancer (1995) 63:883–5.10.1002/ijc.2910630622 [PubMed] [Cross Ref]
36. Bricard G, Bouzourene H, Martinet O, Rimoldi D, Halkic N, Gillet M, et al. Naturally acquired MAGE-A10- and SSX-2-specific CD8+ T cell responses in patients with hepatocellular carcinoma. J Immunol (2005) 174:1709–16.10.4049/jimmunol.174.3.1709 [PubMed] [Cross Ref]
37. Valmori D, Dutoit V, Rubio-Godoy V, Chambaz C, Lienard D, Guillaume P, et al. Frequent cytolytic T-cell responses to peptide MAGE-A10(254-262) in melanoma. Cancer Res (2001) 61:509–12. [PubMed]
38. Groeper C, Gambazzi F, Zajac P, Bubendorf L, Adamina M, Rosenthal R, et al. Cancer/testis antigen expression and specific cytotoxic T lymphocyte responses in non small cell lung cancer. Int J Cancer (2007) 120:337–43.10.1002/ijc.22309 [PubMed] [Cross Ref]
39. Graff-Dubois S, Faure O, Gross DA, Alves P, Scardino A, Chouaib S, et al. Generation of CTL recognizing an HLA-A*0201-restricted epitope shared by MAGE-A1, -A2, -A3, -A4, -A6, -A10, and -A12 tumor antigens: implication in a broad-spectrum tumor immunotherapy. J Immunol (2002) 169:575–80.10.4049/jimmunol.169.1.575 [PubMed] [Cross Ref]
40. Gros A, Parkhurst MR, Tran E, Pasetto A, Robbins PF, Ilyas S, et al. Prospective identification of neoantigen-specific lymphocytes in the peripheral blood of melanoma patients. Nat Med (2016) 22:433–8.10.1038/nm.4051 [PubMed] [Cross Ref]
41. Vansteenkiste JF, Cho BC, Vanakesa T, De Pas TM, Zielinski M, Kim MS, et al. Efficacy of the MAGE-A3 cancer immunotherapeutic as adjuvant therapy in patients with resected MAGE-A3-positive non-small-cell lung cancer (MAGRIT): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol (2016) 17:822–35.10.1016/S1470-2045(16)00099-1 [PubMed] [Cross Ref]
42. Kruit WH, Suciu S, Dreno B, Mortier L, Robert C, Chiarion-Sileni V, et al. Selection of immunostimulant AS15 for active immunization with MAGE-A3 protein: results of a randomized phase II study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma. J Clin Oncol (2013) 31:2413–20.10.1200/JCO.2012.43.7111 [PubMed] [Cross Ref]
43. Germeau C, Ma W, Schiavetti F, Lurquin C, Henry E, Vigneron N, et al. High frequency of antitumor T cells in the blood of melanoma patients before and after vaccination with tumor antigens. J Exp Med (2005) 201:241–8.10.1084/jem.20041379 [PMC free article] [PubMed] [Cross Ref]
44. Marchand M, Van BN, Weynants P, Brichard V, Dreno B, Tessier MH, et al. Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by gene MAGE-3 and presented by HLA-A1. Int J Cancer (1999) 80:219–30.10.1002/(SICI)1097-0215(19990118)80:2<219::AID-IJC10>3.3.CO;2-J [PubMed] [Cross Ref]
45. Schuler-Thurner B, Dieckmann D, Keikavoussi P, Bender A, Maczek C, Jonuleit H, et al. Mage-3 and influenza-matrix peptide-specific cytotoxic T cells are inducible in terminal stage HLA-A2.1+ melanoma patients by mature monocyte-derived dendritic cells. J Immunol (2000) 165:3492–6.10.4049/jimmunol.165.6.3492 [PubMed] [Cross Ref]
46. Russo V, Pilla L, Lunghi F, Crocchiolo R, Greco R, Ciceri F, et al. Clinical and immunologic responses in melanoma patients vaccinated with MAGE-A3-genetically modified lymphocytes. Int J Cancer (2013) 132:2557–66.10.1002/ijc.27939 [PubMed] [Cross Ref]
47. Wilgenhof S, Corthals J, Heirman C, Van Baren N, Lucas S, Kvistborg P, et al. Phase II study of autologous monocyte-derived mRNA electroporated dendritic cells (TriMixDC-MEL) plus ipilimumab in patients with pretreated advanced melanoma. J Clin Oncol (2016) 34:1330–8.10.1200/JCO.2015.63.4121 [PubMed] [Cross Ref]
48. Batchu RB, Gruzdyn OV, Moreno-Bost AM, Szmania S, Jayandharan G, Srivastava A, et al. Efficient lysis of epithelial ovarian cancer cells by MAGE-A3-induced cytotoxic T lymphocytes using rAAV-6 capsid mutant vector. Vaccine (2014) 32:938–43.10.1016/j.vaccine.2013.12.049 [PubMed] [Cross Ref]
49. Lin L, Wei J, Chen Y, Huang A, Li KK, Zhang W.. Induction of antigen-specific immune responses by dendritic cells transduced with a recombinant lentiviral vector encoding MAGE-A3 gene. J Cancer Res Clin Oncol (2014) 140:281–9.10.1007/s00432-013-1552-8 [PubMed] [Cross Ref]
50. Rapoport AP, Aqui NA, Stadtmauer EA, Vogl DT, Xu YY, Kalos M, et al. Combination immunotherapy after ASCT for multiple myeloma using MAGE-A3/Poly-ICLC immunizations followed by adoptive transfer of vaccine-primed and costimulated autologous T cells. Clin Cancer Res (2014) 20:1355–65.10.1158/1078-0432.CCR-13-2817 [PMC free article] [PubMed] [Cross Ref]
51. Connerotte T, Van PA, Godelaine D, Tartour E, Schuler-Thurner B, Lucas S, et al. Functions of Anti-MAGE T-cells induced in melanoma patients under different vaccination modalities. Cancer Res (2008) 68:3931–40.10.1158/0008-5472.CAN-07-5898 [PubMed] [Cross Ref]
52. Brichard VG, Lejeune D.. GSK’s antigen-specific cancer immunotherapy programme: pilot results leading to Phase III clinical development. Vaccine (2007) 25(Suppl 2):B61–71.10.1016/j.vaccine.2007.06.038 [PubMed] [Cross Ref]
53. Brichard VG, Godechal Q.. MAGE-A3-specific anticancer immunotherapy in the clinical practice. Oncoimmunology (2013) 2:e25995.10.4161/onci.25995 [PMC free article] [PubMed] [Cross Ref]
54. Vansteenkiste J, Zielinski M, Linder A, Dahabreh J, Gonzalez EE, Malinowski W, et al. Adjuvant MAGE-A3 immunotherapy in resected non-small-cell lung cancer: phase II randomized study results. J Clin Oncol (2013) 31:2396–403.10.1200/JCO.2012.43.7103 [PubMed] [Cross Ref]
55. Scanlan MJ, Gure AO, Jungbluth AA, Old LJ, Chen YT.. Cancer/testis antigens: an expanding family of targets for cancer immunotherapy. Immunol Rev (2002) 188:22–32.10.1034/j.1600-065X.2002.18803.x [PubMed] [Cross Ref]
56. Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases – elimination, equilibrium and escape. Curr Opin Immunol (2014) 27:16–25.10.1016/j.coi.2014.01.004 [PMC free article] [PubMed] [Cross Ref]
57. Corbiere V, Chapiro J, Stroobant V, Ma W, Lurquin C, Lethe B, et al. Antigen spreading contributes to MAGE vaccination-induced regression of melanoma metastases. Cancer Res (2011) 71:1253–62.10.1158/0008-5472.CAN-10-2693 [PubMed] [Cross Ref]
58. Kenter GG, Welters MJ, Valentijn AR, Lowik MJ, Berends-van der Meer D, Vloon AP, et al. Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia. N Engl J Med (2009) 361:1838–47.10.1056/NEJMoa0810097 [PubMed] [Cross Ref]
59. Adamina M, Rosenthal R, Weber WP, Frey DM, Viehl CT, Bolli M, et al. Intranodal immunization with a vaccinia virus encoding multiple antigenic epitopes and costimulatory molecules in metastatic melanoma. Mol Ther (2010) 18:651–9.10.1038/mt.2009.275 [PubMed] [Cross Ref]
60. Brisam M, Rauthe S, Hartmann S, Linz C, Brands RC, Kubler AC, et al. Expression of MAGE-A1-A12 subgroups in the invasive tumor front and tumor center in oral squamous cell carcinoma. Oncol Rep (2016) 35:1979–86.10.3892/or.2016.4600 [PubMed] [Cross Ref]
61. Weiser TS, Ohnmacht GA, Guo ZS, Fischette MR, Chen GA, Hong JA, et al. Induction of MAGE-3 expression in lung and esophageal cancer cells. Ann Thorac Surg (2001) 71:295–301.10.1016/S0003-4975(00)02421-8 [PubMed] [Cross Ref]
62. Brichard VG, Louahed J, Clay TM. Cancer regression and neurological toxicity cases after anti-MAGE-A3 TCR gene therapy. J Immunother (2013) 36:79–81.10.1097/CJI.0b013e3182829747 [PubMed] [Cross Ref]
63. Cameron BJ, Gerry AB, Dukes J, Harper JV, Kannan V, Bianchi FC, et al. Identification of a Titin-derived HLA-A1-presented peptide as a cross-reactive target for engineered MAGE A3-directed T cells. Sci Transl Med (2013) 5:197ra103.10.1126/scitranslmed.3006034 [PubMed] [Cross Ref]
64. Linette GP, Stadtmauer EA, Maus MV, Rapoport AP, Levine BL, Emery L, et al. Cardiovascular toxicity and titin cross-reactivity of affinity-enhanced T cells in myeloma and melanoma. Blood (2013) 122:863–71.10.1182/blood-2013-03-490565 [PubMed] [Cross Ref]
65. Chinnasamy N, Wargo JA, Yu Z, Rao M, Frankel TL, Riley JP, et al. A TCR targeting the HLA-A*0201-restricted epitope of MAGE-A3 recognizes multiple epitopes of the MAGE-A antigen superfamily in several types of cancer. J Immunol (2011) 186:685–96.10.4049/jimmunol.1001775 [PubMed] [Cross Ref]
66. Karanikas V, Lurquin C, Colau D, VanBaren N, DeSmet C, Lethe B, et al. Monoclonal anti-MAGE-3 CTL responses in melanoma patients displaying tumor regression after vaccination with a recombinant canarypox virus. J Immunol (2003) 171:4898–904.10.4049/jimmunol.171.9.4898 [PubMed] [Cross Ref]
67. Kageyama S, Ikeda H, Miyahara Y, Imai N, Ishihara M, Saito K, et al. Adoptive transfer of MAGE-A4 T-cell receptor gene-transduced lymphocytes in patients with recurrent esophageal cancer. Clin Cancer Res (2015) 21:2268–77.10.1158/1078-0432.CCR-14-1559 [PubMed] [Cross Ref]
68. Furness AJ, Vargas FA, Peggs KS, Quezada SA.. Impact of tumour microenvironment and Fc receptors on the activity of immunomodulatory antibodies. Trends Immunol (2014) 35:290–8.10.1016/j.it.2014.05.002 [PubMed] [Cross Ref]
69. Korman AJ, Peggs KS, Allison JP.. Checkpoint blockade in cancer immunotherapy. Adv Immunol (2006) 90:297–339.10.1016/S0065-2776(06)90008-X [PMC free article] [PubMed] [Cross Ref]
70. Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky JM, Desrichard A, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med (2014) 371:2189–99.10.1056/NEJMoa1406498 [PMC free article] [PubMed] [Cross Ref]
71. Kreiter S, Vormehr M, van de Roemer N, Diken M, Lower M, Diekmann J, et al. Mutant MHC class II epitopes drive therapeutic immune responses to cancer. Nature (2015) 520:692–6.10.1038/nature14426 [PMC free article] [PubMed] [Cross Ref]
72. Mennonna D, Maccalli C, Romano MC, Garavaglia C, Capocefalo F, Bordoni R, et al. T cell neoepitope discovery in colorectal cancer by high throughput profiling of somatic mutations in expressed genes. Gut (2017) 66(3):454–63.10.1136/gutjnl-2015-309453 [PubMed] [Cross Ref]
73. Verdegaal EM, de Miranda NF, Visser M, Harryvan T, van Buuren MM, Andersen RS, et al. Neoantigen landscape dynamics during human melanoma-T cell interactions. Nature (2016) 536:91–5.10.1038/nature18945 [PubMed] [Cross Ref]
74. Walter S, Weinschenk T, Stenzl A, Zdrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med (2012) 18:1254–61.10.1038/nm.2883 [PubMed] [Cross Ref]
75. Britten CM, Singh-Jasuja H, Flamion B, Hoos A, Huber C, Kallen KJ, et al. The regulatory landscape for actively personalized cancer immunotherapies. Nat Biotechnol (2013) 31:880–2.10.1038/nbt.2708 [PubMed] [Cross Ref]
76. Romero P, Banchereau J, Bhardwaj N, Cockett M, Disis ML, Dranoff G, et al. The Human Vaccines Project: a roadmap for cancer vaccine development. Sci Transl Med (2016) 8:334s9.10.1126/scitranslmed.aaf0685 [PubMed] [Cross Ref]

Articles from Frontiers in Medicine are provided here courtesy of Frontiers Media SA